Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy

被引:51
作者
Modi, Ankita [1 ]
Siris, Ethel S. [2 ,3 ]
Tang, Jackson [4 ]
Sen, Shuvayu [1 ]
机构
[1] Merck & Co Inc, Lebanon, NJ 08833 USA
[2] Columbia Univ, Med Ctr, Toni Stabile Osteoporosis Ctr, New York, NY USA
[3] NY Presbyterian Hosp, New York, NY USA
[4] Asclepius Analyt Ltd, New York, NY USA
关键词
Adherence; Compliance; Fracture risk; Healthcare costs; Healthcare utilization; Osteoporosis; HEALTH-CARE COSTS; BISPHOSPHONATE THERAPY; FRACTURE RATES; UNITED-STATES; ADHERENCE; MEDICATION; INTERVENTION; PERSISTENCE; MANAGEMENT; RISK;
D O I
10.1185/03007995.2015.1016605
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Objective: The objective was to evaluate compliance with osteoporosis (OP) treatments and determine the fracture and healthcare burden associated with noncompliance. Methods: This retrospective analysis of a US claims database identified women initiating an OP medication from 1 January 2002 to 30 June 2009. Patients were >= 55 years and had >= 1 pharmacy claim for a bisphosphonate or non-bisphosphonate (raloxifene, calcitonin, teriparatide); the index date was the first pharmacy claim. There were three study periods: baseline (12 months pre-index); compliance period (0-12 months post-index); and follow-up period (12-24 months post-index). Medication possession ratio (MPR) was calculated during the compliance period to differentiate two cohorts: compliant (MPR >= 80%) and noncompliant (MPR<80%). Outcomes during follow-up were modeled by logistic regression (presence of fracture), Poisson regression (healthcare utilization incidence rate) and gamma regression (healthcare costs), all adjusted for patient demographic and clinical characteristics. Results: Overall, 685,505 women initiating OP therapy were identified and 57,913 (8.4%) met the inclusion criteria: only 23,430 (40.5%) were compliant and 34,483 (59.5%) were noncompliant. Mean age was 64 years. Noncompliance was associated with a 20% higher risk of any fracture (odds ratio: 1.20, 95% CI = 1.07-1.35), a higher incidence rate ratio (IRR) for inpatient utilization (IRR: 1.26, 95% CI = 1.19-1.34) and a lower rate of outpatient utilization (IRR: 0.97, 95% CI = 0.95-0.98). Noncompliant patients had 13% higher medical costs (cost ratio: 1.13, 95% CI = 1.06-1.21) than compliant patients. Limitations: Inclusion in this study required 36 months of continuous healthcare coverage. Thus, the results are primarily applicable to a stable, managed care population and may not be generalizable to other populations. Conclusion: Noncompliance with OP therapy was associated with a higher risk of fracture, higher all-cause medical costs and a higher frequency of inpatient service utilization. Additional research is needed to identify barriers to compliance with OP therapy.
引用
收藏
页码:757 / 765
页数:9
相关论文
共 27 条
[1]
[Anonymous], 2014, CLIN GUID PREV TREAT
[2]
Loss of treatment benefit due to low compliance with bisphosphonate therapy [J].
Beest, F. J. A. Penning-van ;
Erkens, J. A. ;
Olson, M. ;
Herings, R. M. C. .
OSTEOPOROSIS INTERNATIONAL, 2008, 19 (04) :511-517
[3]
Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study [J].
Blouin, J. ;
Dragomir, A. ;
Fredette, M. ;
Ste-Marie, L. -G. ;
Fernandes, J. C. ;
Perreault, S. .
OSTEOPOROSIS INTERNATIONAL, 2009, 20 (09) :1571-1581
[4]
Consequences of poor compliance with bisphosphonates [J].
Briesacher, Becky A. ;
Andrade, Susan E. ;
Yood, Robert A. ;
Kahler, Kristijan H. .
BONE, 2007, 41 (05) :882-887
[5]
Adherence to lipid-lowering therapy and the use of preventive health services: An investigation of the healthy user effect [J].
Brookhart, M. Alan ;
Patrick, Amanda R. ;
Dormuth, Colin ;
Avorn, Jerry ;
Shrank, William ;
Cadarette, Suzanne M. ;
Solomon, Daniel H. .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2007, 166 (03) :348-354
[6]
Osteoporotic fractures: A systematic review of US healthcare costs and resource utilization [J].
Sangeeta Budhia ;
Yeshi Mikyas ;
Michael Tang ;
Enkhe Badamgarav .
PharmacoEconomics, 2012, 30 (2) :147-170
[7]
Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
[8]
Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis [J].
Cramer, JA ;
Amonkar, MM ;
Hebborn, A ;
Altman, R .
CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (09) :1453-1460
[9]
A prospective clinical practice intervention to improve osteoporosis management following distal forearm fracture [J].
Cuddihy, MT ;
Amadio, PC ;
Gabriel, SE ;
Pankratz, VS ;
Kurland, RL ;
Melton, LJ .
OSTEOPOROSIS INTERNATIONAL, 2004, 15 (09) :695-700
[10]
Identification and Validation of Vertebral Compression Fractures Using Administrative Claims Data [J].
Curtis, Jeffrey R. ;
Mudano, Amy S. ;
Solomon, Daniel H. ;
Xi, Juan ;
Melton, Elkins ;
Saag, Kenneth G. .
MEDICAL CARE, 2009, 47 (01) :69-72